Rajeev Chillakuru
Plus aucun poste en cours
Profil
Rajeev Chillakuru is Vice President of Process Development and Manufacturing for Virdante Pharmaceuticals, Inc. Most recently, he was Senior Director of Glycoprotein Program for Momenta Pharmaceuticals, Inc. Prior to joining Momenta Pharmaceuticals, he was Executive Director of Bioprocess Development and Manufacturing for Halozyme Therapeutics, Inc. Previously, he was Director of Manufacturing for CuraGen Corp.
from 1999 to 2004 and Dow Biomanufacturing Services from 1997 to 1999.
He has over 15 years of process development and biologics manufacturing experience.
Mr. Chillakuru received a degree in Chemical Engineering from the State University of New York in 1991.
Anciens postes connus de Rajeev Chillakuru
| Sociétés | Poste | Fin |
|---|---|---|
Virdante Pharmaceuticals, Inc.
 Virdante Pharmaceuticals, Inc. Medical DistributorsDistribution Services Virdante Pharmaceuticals, Inc. develops and commercializes drugs for auto-immune and inflammatory disorders. The company's products incorporate a proprietary 'sialic switch' technology to improve the anti-inflammatory properties of antibodies. It was founded in 2008 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | 31/01/2012 |
CuraGen Corp.
 CuraGen Corp. Pharmaceuticals: MajorHealth Technology CuraGen Corp. develops protein, antibody and small molecule pharmaceutical products. The firm focuses on the development of CR011-vcMMAE, a Phase II clinical trial drug for the treatment of patients with metastatic melanoma and breast cancer. The company was founded in 1991 and is headquartered in Branford, CT. | Corporate Officer/Principal | 01/01/2004 |
| HALOZYME THERAPEUTICS, INC. | Corporate Officer/Principal | - |
| MOMENTA PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
Formation de Rajeev Chillakuru
| State University of New York at Buffalo | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| HALOZYME THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 3 |
|---|---|
Virdante Pharmaceuticals, Inc.
Virdante Pharmaceuticals, Inc. Medical DistributorsDistribution Services Virdante Pharmaceuticals, Inc. develops and commercializes drugs for auto-immune and inflammatory disorders. The company's products incorporate a proprietary 'sialic switch' technology to improve the anti-inflammatory properties of antibodies. It was founded in 2008 and is headquartered in Cambridge, MA. | Distribution Services |
Momenta Pharmaceuticals, Inc.
 Momenta Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Momenta Pharmaceuticals, Inc. operates as a biotechnology company that focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases. Its products include the Glatiramer acetate injection and Enoxaparin Sodium injection. The company was founded by Ram Sasisekharan, Paul R. Schimmel, and Ganesh Venkatraman Kaundinya in May 2001 and is headquartered in Cambridge, MA. | Health Technology |
CuraGen Corp.
CuraGen Corp. Pharmaceuticals: MajorHealth Technology CuraGen Corp. develops protein, antibody and small molecule pharmaceutical products. The firm focuses on the development of CR011-vcMMAE, a Phase II clinical trial drug for the treatment of patients with metastatic melanoma and breast cancer. The company was founded in 1991 and is headquartered in Branford, CT. | Health Technology |